ILMN
Illumina, Inc.
Price Chart
Latest Quote
$181.27
+6.18 (+3.53%)
Current Price
| Previous Close | $175.09 |
| Open | $178.50 |
| Day High | $181.91 |
| Day Low | $177.18 |
| Volume | 85,351 |
Stock Information
| Shares Outstanding | 151.30M |
| Total Debt | $2.54B |
| Cash Equivalents | $1.16B |
| Revenue | $4.39B |
| Net Income | $853.00M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $27.43B |
| P/E Ratio | 32.96 |
| EPS (TTM) | $5.50 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $27.88B |
| Sales | $4.39B |
| Income | $853.00M |
| Book/sh | $17.61 |
| Cash/sh | $7.63 |
| Employees | 9K |
Financial Ratios
| Quick Ratio | 1.23 |
| Current Ratio | 1.75 |
| Debt/Eq | 95.07 |
| EPS Growth TTM | 2.30% |
Returns & Margins
| ROA | 8.68% |
| ROE | 33.82% |
| Gross Margin | 68.29% |
| Operating Margin | 18.33% |
| Profit Margin | 19.42% |
Ownership
| Insider Ownership | 0.20% |
| Institutional Ownership | 106.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 30.56 |
| PEG | 2.81 |
| P/S | 6.24 |
| P/B | 10.30 |
Analyst Data
| Recommendation | buy |
| Target Price | $149.83 |
Technical Indicators
| SMA20 | $164.62 |
| SMA50 | $148.19 |
| SMA200 | $128.17 |
| RSI | 60.93 |
| ATR | 6.7664 |
| Shares Float | 148.03M |
| Short Float | 8.34% |
| Short Ratio | 4.24 |
| Volatility | 1.49 |
| Rel Volume | 0.04 |
Performance History
| Week | +13.94% |
| Month | +24.82% |
| Quarter | +43.64% |
| 6 Months | +31.74% |
| YTD | +34.92% |
| Year | +98.07% |
| 3 Years | -7.81% |
| 5 Years | -59.08% |
| 10 Years | +37.54% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $181.27 | 85,354 |
| 2026-06-24 | $175.09 | 2,645,700 |
| 2026-06-23 | $164.93 | 2,062,200 |
| 2026-06-22 | $161.38 | 1,791,200 |
| 2026-06-18 | $161.93 | 3,100,600 |
| 2026-06-17 | $159.09 | 1,592,600 |
| 2026-06-16 | $164.28 | 1,269,900 |
| 2026-06-15 | $166.89 | 2,159,200 |
| 2026-06-12 | $160.97 | 1,498,400 |
| 2026-06-11 | $166.21 | 1,486,900 |
| 2026-06-10 | $162.47 | 2,757,700 |
| 2026-06-09 | $160.03 | 1,455,100 |
| 2026-06-08 | $158.04 | 1,263,500 |
| 2026-06-05 | $162.32 | 2,061,500 |
| 2026-06-04 | $168.06 | 2,606,100 |
| 2026-06-03 | $170.93 | 3,140,100 |
| 2026-06-02 | $162.55 | 2,132,800 |
| 2026-06-01 | $164.40 | 2,190,500 |
| 2026-05-29 | $162.96 | 2,567,400 |
| 2026-05-28 | $158.70 | 2,304,300 |
| 2026-05-27 | $150.17 | 1,891,700 |
| 2026-05-26 | $145.23 | 1,602,500 |
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
đ° Latest News
Why Illumina (ILMN) Stock Is Trading Up Today
StockStory âĸ 2026-06-24T18:56:25Z
Illumina (ILMN) Stock After 80% One-Year Rebound Is The Price Now Justified
Simply Wall St. âĸ 2026-06-24T13:16:02Z
Adding Eli Lillyâs R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)
Simply Wall St. âĸ 2026-06-24T01:12:16Z
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
StockStory âĸ 2026-06-16T14:17:04Z
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Barchart âĸ 2026-06-10T20:38:17Z
Illumina upgraded to overweight at JPMorgan on clinical demand outlook
Investing.com âĸ 2026-06-10T19:43:52ZStocks Resume Decline as Chipmakers and AI Companies Fall
Barchart âĸ 2026-06-10T15:21:45Z
Stocks Fall on Weakness in Tech and Trucking Companies
Barchart âĸ 2026-06-10T14:09:04Z
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-10T13:42:21Z
Nasdaq Futures Plunge as Tech Selloff Deepens, U.S. Inflation Data in Focus
Barchart âĸ 2026-06-10T10:38:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,473,000,000 | $1,511,000,000 | $1,760,000,000 | $1,612,000,000 |
| Cost Of Revenue | $1,473,000,000 | $1,511,000,000 | $1,760,000,000 | $1,612,000,000 |
| Total Revenue | $4,343,000,000 | $4,372,000,000 | $4,504,000,000 | $4,584,000,000 |
| Operating Revenue | $4,343,000,000 | $4,372,000,000 | $4,504,000,000 | $4,584,000,000 |
| Expenses | ||||
| Interest Expense | $101,000,000 | $100,000,000 | $77,000,000 | $26,000,000 |
| Total Expenses | $3,526,000,000 | $3,772,000,000 | $4,726,000,000 | $4,230,000,000 |
| Other Income Expense | $330,000,000 | $-1,725,000,000 | $-876,000,000 | $-4,675,000,000 |
| Other Non Operating Income Expenses | $340,000,000 | $-292,000,000 | $-29,000,000 | $-142,000,000 |
| Net Non Operating Interest Income Expense | $-61,000,000 | $-54,000,000 | $-19,000,000 | $-15,000,000 |
| Interest Expense Non Operating | $101,000,000 | $100,000,000 | $77,000,000 | $26,000,000 |
| Operating Expense | $2,053,000,000 | $2,261,000,000 | $2,966,000,000 | $2,618,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Net Interest Income | $-61,000,000 | $-54,000,000 | $-19,000,000 | $-15,000,000 |
| Interest Income | $40,000,000 | $46,000,000 | $58,000,000 | $11,000,000 |
| Normalized Income | $857,826,888 | $-90,930,000 | $-491,870,000 | $-822,930,000 |
| Net Income From Continuing And Discontinued Operation | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Total Operating Income As Reported | $807,000,000 | $-833,000,000 | $-1,069,000,000 | $-4,179,000,000 |
| Net Income Common Stockholders | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Net Income | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Net Income Including Noncontrolling Interests | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Net Income Continuous Operations | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Pretax Income | $1,086,000,000 | $-1,179,000,000 | $-1,117,000,000 | $-4,336,000,000 |
| Special Income Charges | $-10,000,000 | $-1,433,000,000 | $-847,000,000 | $-4,533,000,000 |
| Interest Income Non Operating | $40,000,000 | $46,000,000 | $58,000,000 | $11,000,000 |
| Operating Income | $817,000,000 | $600,000,000 | $-222,000,000 | $354,000,000 |
| Gross Profit | $2,870,000,000 | $2,861,000,000 | $2,744,000,000 | $2,972,000,000 |
| Per Share | ||||
| Diluted EPS | $5.45 | $-7.69 | $-7.34 | $-28.00 |
| Basic EPS | $5.47 | $-7.69 | $-7.34 | $-28.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,173,112 | $-300,930,000 | $-177,870,000 | $-951,930,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,467,000,000 | $708,000,000 | $239,000,000 | $617,000,000 |
| Total Unusual Items | $-10,000,000 | $-1,433,000,000 | $-847,000,000 | $-4,533,000,000 |
| Total Unusual Items Excluding Goodwill | $-10,000,000 | $-1,433,000,000 | $-847,000,000 | $-4,533,000,000 |
| Reconciled Depreciation | $270,000,000 | $354,000,000 | $432,000,000 | $394,000,000 |
| EBITDA (Bullshit earnings) | $1,457,000,000 | $-725,000,000 | $-608,000,000 | $-3,916,000,000 |
| EBIT | $1,187,000,000 | $-1,079,000,000 | $-1,040,000,000 | $-4,310,000,000 |
| Diluted Average Shares | $156,000,000 | $159,000,000 | $158,000,000 | $157,000,000 |
| Basic Average Shares | $155,000,000 | $159,000,000 | $158,000,000 | $157,000,000 |
| Diluted NI Availto Com Stockholders | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Tax Provision | $236,000,000 | $44,000,000 | $44,000,000 | $68,000,000 |
| Other Special Charges | $10,000,000 | $-456,000,000 | $20,000,000 | $619,000,000 |
| Impairment Of Capital Assets | $0 | $1,889,000,000 | $827,000,000 | $3,914,000,000 |
| Research And Development | $967,000,000 | $1,169,000,000 | $1,354,000,000 | $1,321,000,000 |
| Selling General And Administration | $1,086,000,000 | $1,092,000,000 | $1,612,000,000 | $1,297,000,000 |
| Restructuring And Mergern Acquisition | - | - | $0 | $0 |
| Gain On Sale Of Security | - | - | $-30,000,000 | $-129,000,000 |
| Minority Interests | - | - | - | - |
| Gain On Sale Of Business | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,400,000,000 | $965,000,000 | $207,000,000 | $75,000,000 |
| Total Assets | $6,644,000,000 | $6,303,000,000 | $10,111,000,000 | $12,252,000,000 |
| Total Non Current Assets | $3,355,000,000 | $3,557,000,000 | $7,502,000,000 | $8,691,000,000 |
| Other Non Current Assets | $449,000,000 | $348,000,000 | $357,000,000 | $423,000,000 |
| Non Current Deferred Assets | $454,000,000 | $567,000,000 | $56,000,000 | - |
| Non Current Deferred Taxes Assets | $454,000,000 | $567,000,000 | $56,000,000 | - |
| Goodwill And Other Intangible Assets | $1,323,000,000 | $1,408,000,000 | $5,538,000,000 | $6,524,000,000 |
| Other Intangible Assets | $210,000,000 | $295,000,000 | $2,993,000,000 | $3,285,000,000 |
| Current Assets | $3,289,000,000 | $2,746,000,000 | $2,609,000,000 | $3,561,000,000 |
| Other Current Assets | $238,000,000 | $244,000,000 | $234,000,000 | $285,000,000 |
| Inventory | $564,000,000 | $547,000,000 | $587,000,000 | $568,000,000 |
| Receivables | $854,000,000 | $735,000,000 | $734,000,000 | $671,000,000 |
| Accounts Receivable | $854,000,000 | $735,000,000 | $734,000,000 | $671,000,000 |
| Allowance For Doubtful Accounts Receivable | $-7,000,000 | $-9,000,000 | $-7,000,000 | $-4,000,000 |
| Gross Accounts Receivable | $861,000,000 | $744,000,000 | $741,000,000 | $675,000,000 |
| Cash Cash Equivalents And Short Term Investments | $1,633,000,000 | $1,220,000,000 | $1,054,000,000 | $2,037,000,000 |
| Cash And Cash Equivalents | $1,418,000,000 | $1,127,000,000 | $1,048,000,000 | $2,011,000,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $571,000,000 | $862,000,000 | $441,000,000 | $724,000,000 |
| Total Debt | $2,553,000,000 | $2,622,000,000 | $2,262,000,000 | $3,555,000,000 |
| Long Term Debt And Capital Lease Obligation | $1,976,000,000 | $2,044,000,000 | $2,176,000,000 | $2,231,000,000 |
| Long Term Debt | $1,490,000,000 | $1,490,000,000 | $1,489,000,000 | $1,487,000,000 |
| Current Debt And Capital Lease Obligation | $577,000,000 | $578,000,000 | $86,000,000 | $1,324,000,000 |
| Current Debt | $499,000,000 | $499,000,000 | - | $1,248,000,000 |
| Other Current Borrowings | $499,000,000 | $499,000,000 | - | $1,248,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,921,000,000 | $3,930,000,000 | $4,366,000,000 | $5,653,000,000 |
| Total Non Current Liabilities Net Minority Interest | $2,336,000,000 | $2,383,000,000 | $2,796,000,000 | $2,880,000,000 |
| Other Non Current Liabilities | $360,000,000 | $339,000,000 | $620,000,000 | $649,000,000 |
| Current Liabilities | $1,585,000,000 | $1,547,000,000 | $1,570,000,000 | $2,773,000,000 |
| Current Deferred Liabilities | $270,000,000 | $260,000,000 | $252,000,000 | $245,000,000 |
| Payables And Accrued Expenses | $489,000,000 | $457,000,000 | $1,009,000,000 | $1,016,000,000 |
| Payables | $347,000,000 | $322,000,000 | $324,000,000 | $390,000,000 |
| Total Tax Payable | $107,000,000 | $101,000,000 | $79,000,000 | $97,000,000 |
| Accounts Payable | $240,000,000 | $221,000,000 | $245,000,000 | $293,000,000 |
| Current Notes Payable | - | - | - | $500,000,000 |
| Equity | ||||
| Common Stock Equity | $2,723,000,000 | $2,373,000,000 | $5,745,000,000 | $6,599,000,000 |
| Total Equity Gross Minority Interest | $2,723,000,000 | $2,373,000,000 | $5,745,000,000 | $6,599,000,000 |
| Stockholders Equity | $2,723,000,000 | $2,373,000,000 | $5,745,000,000 | $6,599,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-10,000,000 | $22,000,000 | $-1,000,000 | $3,000,000 |
| Other Equity Adjustments | $-10,000,000 | $22,000,000 | $-1,000,000 | $3,000,000 |
| Retained Earnings | $-392,000,000 | $-1,242,000,000 | $-19,000,000 | $1,142,000,000 |
| Other | ||||
| Treasury Shares Number | $48,000,000 | $41,000,000 | $40,000,000 | $40,000,000 |
| Ordinary Shares Number | $153,000,000 | $159,000,000 | $159,000,000 | $158,000,000 |
| Share Issued | $201,000,000 | $200,000,000 | $199,000,000 | $198,000,000 |
| Tangible Book Value | $1,400,000,000 | $965,000,000 | $207,000,000 | $75,000,000 |
| Invested Capital | $4,712,000,000 | $4,362,000,000 | $7,234,000,000 | $9,334,000,000 |
| Working Capital | $1,704,000,000 | $1,199,000,000 | $1,039,000,000 | $788,000,000 |
| Capital Lease Obligations | $564,000,000 | $633,000,000 | $773,000,000 | $820,000,000 |
| Total Capitalization | $4,213,000,000 | $3,863,000,000 | $7,234,000,000 | $8,086,000,000 |
| Treasury Stock | $4,699,000,000 | $3,934,000,000 | $3,792,000,000 | $3,755,000,000 |
| Additional Paid In Capital | $7,822,000,000 | $7,525,000,000 | $9,555,000,000 | $9,207,000,000 |
| Capital Stock | $2,000,000 | $2,000,000 | $2,000,000 | $2,000,000 |
| Common Stock | $2,000,000 | $2,000,000 | $2,000,000 | $2,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $486,000,000 | $554,000,000 | $687,000,000 | $744,000,000 |
| Current Deferred Revenue | $270,000,000 | $260,000,000 | $252,000,000 | $245,000,000 |
| Current Capital Lease Obligation | $78,000,000 | $79,000,000 | $86,000,000 | $76,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $249,000,000 | $252,000,000 | $223,000,000 | $188,000,000 |
| Current Accrued Expenses | $142,000,000 | $135,000,000 | $685,000,000 | $626,000,000 |
| Goodwill | $1,113,000,000 | $1,113,000,000 | $2,545,000,000 | $3,239,000,000 |
| Net PPE | $1,129,000,000 | $1,234,000,000 | $1,551,000,000 | $1,744,000,000 |
| Accumulated Depreciation | $-1,363,000,000 | $-1,254,000,000 | $-1,138,000,000 | $-962,000,000 |
| Gross PPE | $2,492,000,000 | $2,488,000,000 | $2,689,000,000 | $2,706,000,000 |
| Leases | $755,000,000 | $772,000,000 | $803,000,000 | $759,000,000 |
| Construction In Progress | $82,000,000 | $39,000,000 | $96,000,000 | $132,000,000 |
| Other Properties | $370,000,000 | $419,000,000 | $544,000,000 | $653,000,000 |
| Machinery Furniture Equipment | $1,241,000,000 | $1,214,000,000 | $1,202,000,000 | $1,118,000,000 |
| Buildings And Improvements | $44,000,000 | $44,000,000 | $44,000,000 | $44,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-133,000,000 | $-113,000,000 | $-121,000,000 | $-93,000,000 |
| Finished Goods | $45,000,000 | $31,000,000 | $30,000,000 | $28,000,000 |
| Work In Process | $398,000,000 | $404,000,000 | $402,000,000 | $386,000,000 |
| Raw Materials | $254,000,000 | $225,000,000 | $276,000,000 | $247,000,000 |
| Other Short Term Investments | $215,000,000 | $93,000,000 | $6,000,000 | $26,000,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $931,000,000 | $709,000,000 | $283,000,000 | $106,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,079,000,000 | $837,000,000 | $478,000,000 | $392,000,000 |
| Cash Flow From Continuing Operating Activities | $1,079,000,000 | $837,000,000 | $478,000,000 | $392,000,000 |
| Operating Gains Losses | $-328,000,000 | $312,000,000 | $40,000,000 | $122,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-148,000,000 | $-128,000,000 | $-195,000,000 | $-286,000,000 |
| Investing Cash Flow | $-55,000,000 | $-178,000,000 | $-231,000,000 | $-591,000,000 |
| Cash Flow From Continuing Investing Activities | $-55,000,000 | $-178,000,000 | $-231,000,000 | $-591,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-742,000,000 | $-116,000,000 | $0 | $0 |
| Issuance Of Capital Stock | $44,000,000 | $56,000,000 | $67,000,000 | $63,000,000 |
| Financing Cash Flow | $-744,000,000 | $-570,000,000 | $-1,210,000,000 | $1,000,000,000 |
| Cash Flow From Continuing Financing Activities | $-744,000,000 | $-570,000,000 | $-1,210,000,000 | $1,000,000,000 |
| Net Other Financing Charges | $-41,000,000 | $-1,001,000,000 | $-41,000,000 | $-54,000,000 |
| Net Common Stock Issuance | $-698,000,000 | $-60,000,000 | $67,000,000 | $63,000,000 |
| Common Stock Issuance | $44,000,000 | $56,000,000 | $67,000,000 | $63,000,000 |
| Other | ||||
| Repayment Of Debt | $-500,000,000 | $-750,000,000 | $-1,236,000,000 | $0 |
| Issuance Of Debt | $495,000,000 | $1,241,000,000 | $0 | $991,000,000 |
| Interest Paid Supplemental Data | $95,000,000 | $83,000,000 | $73,000,000 | $17,000,000 |
| Income Tax Paid Supplemental Data | $73,000,000 | $105,000,000 | $65,000,000 | $122,000,000 |
| End Cash Position | $1,418,000,000 | $1,127,000,000 | $1,048,000,000 | $2,011,000,000 |
| Beginning Cash Position | $1,127,000,000 | $1,048,000,000 | $2,011,000,000 | $1,232,000,000 |
| Effect Of Exchange Rate Changes | $11,000,000 | $-10,000,000 | $0 | $-22,000,000 |
| Changes In Cash | $280,000,000 | $89,000,000 | $-963,000,000 | $801,000,000 |
| Common Stock Payments | $-742,000,000 | $-116,000,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-5,000,000 | $491,000,000 | $-1,236,000,000 | $991,000,000 |
| Net Long Term Debt Issuance | $-5,000,000 | $491,000,000 | $-1,236,000,000 | $991,000,000 |
| Long Term Debt Payments | $-500,000,000 | $-750,000,000 | $-1,236,000,000 | $0 |
| Long Term Debt Issuance | $495,000,000 | $1,241,000,000 | $0 | $991,000,000 |
| Net Investment Purchase And Sale | $103,000,000 | $-52,000,000 | $-6,000,000 | $-40,000,000 |
| Net Business Purchase And Sale | $-10,000,000 | $2,000,000 | $-30,000,000 | $-265,000,000 |
| Sale Of Business | $0 | $83,000,000 | $0 | $0 |
| Purchase Of Business | $-10,000,000 | $-81,000,000 | $-30,000,000 | $-265,000,000 |
| Net PPE Purchase And Sale | $-148,000,000 | $-128,000,000 | $-195,000,000 | $-286,000,000 |
| Purchase Of PPE | $-148,000,000 | $-128,000,000 | $-195,000,000 | $-286,000,000 |
| Change In Working Capital | $-153,000,000 | $-483,000,000 | $-90,000,000 | $204,000,000 |
| Change In Other Working Capital | $-34,000,000 | $-32,000,000 | $-16,000,000 | $-8,000,000 |
| Change In Other Current Liabilities | $33,000,000 | $28,000,000 | $-1,000,000 | $-19,000,000 |
| Change In Other Current Assets | $-21,000,000 | $-15,000,000 | $5,000,000 | $19,000,000 |
| Change In Payables And Accrued Expense | $2,000,000 | $-444,000,000 | $-29,000,000 | $343,000,000 |
| Change In Accrued Expense | $0 | $-440,000,000 | $15,000,000 | $381,000,000 |
| Change In Payable | $2,000,000 | $-4,000,000 | $-44,000,000 | $-38,000,000 |
| Change In Account Payable | $2,000,000 | $-4,000,000 | $-44,000,000 | $-38,000,000 |
| Change In Prepaid Assets | $-8,000,000 | $-14,000,000 | $11,000,000 | $16,000,000 |
| Change In Inventory | $-17,000,000 | $19,000,000 | $-20,000,000 | $-135,000,000 |
| Change In Receivables | $-108,000,000 | $-25,000,000 | $-40,000,000 | $-12,000,000 |
| Changes In Account Receivables | $-108,000,000 | $-25,000,000 | $-40,000,000 | $-12,000,000 |
| Other Non Cash Items | $19,000,000 | $-316,000,000 | $-17,000,000 | $-190,000,000 |
| Stock Based Compensation | $275,000,000 | $370,000,000 | $380,000,000 | $366,000,000 |
| Asset Impairment Charge | $27,000,000 | $1,935,000,000 | $927,000,000 | $3,923,000,000 |
| Deferred Tax | $119,000,000 | $-112,000,000 | $-33,000,000 | $-23,000,000 |
| Deferred Income Tax | $119,000,000 | $-112,000,000 | $-33,000,000 | $-23,000,000 |
| Depreciation Amortization Depletion | $270,000,000 | $354,000,000 | $432,000,000 | $394,000,000 |
| Depreciation And Amortization | $270,000,000 | $354,000,000 | $432,000,000 | $394,000,000 |
| Amortization Cash Flow | $67,000,000 | $130,000,000 | $197,000,000 | $179,000,000 |
| Amortization Of Intangibles | $67,000,000 | $130,000,000 | $197,000,000 | $179,000,000 |
| Depreciation | $203,000,000 | $224,000,000 | $235,000,000 | $215,000,000 |
| Gain Loss On Investment Securities | $-328,000,000 | $312,000,000 | $40,000,000 | $122,000,000 |
| Net Income From Continuing Operations | $850,000,000 | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 |
| Purchase Of Investment | - | $-52,000,000 | $-6,000,000 | $-40,000,000 |
| Sale Of Investment | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $-1,000,000 | $-180,000,000 |
| Purchase Of Intangibles | - | - | $-1,000,000 | $-180,000,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $22,000,000 | $1,000,000 |
| Earnings Losses From Equity Investments | - | - | $0 | $0 |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-20